3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Interventions
Doxorubicin
13
Specimen Handling
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
10
Biopsy
10
Cyclophosphamide
9
X-Rays
7
Ifosfamide
7
Radiotherapy
6
Phantoms, Imaging
6
Gemcitabine
6
liposomal doxorubicin
5
Nivolumab
5
tazemetostat
4
palbociclib
4
fludarabine
4
atezolizumab
4
Temozolomide
4
Radiation
4
Nuclear Medicine Department, Hospital
4
Irinotecan
4
larotrectinib
3
cabozantinib
3
Surveys and Questionnaires
3
Ipilimumab
3
Carboplatin
3
Bevacizumab
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
CLR1404
×
90 days
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled